Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria + tetanus + acellular pertussis vaccine
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Diphtheria + tetanus + acellular pertussis vaccine is a combination immunizing agent used to protect against three serious bacterial diseases: diphtheria, tetanus (lockjaw), and pertussis (whooping cough). The "acellular" component refers to the use of purified antigens from Bordetella pertussis rather than whole-cell preparations, reducing side effects. The mechanism of action involves stimulating the immune system to produce antibodies against toxins produced by Corynebacterium diphtheriae (diphtheria), Clostridium tetani (tetanus), and Bordetella pertussis (pertussis). This results in immunity that prevents infection or reduces disease severity upon exposure. There are two main formulations: DTaP for children under 7 years old and Tdap as a booster for older children, adolescents, and adults[3][5][8]. These vaccines are widely recommended as part of routine immunization schedules.
- Brand names
- DaptacelInfanrixTripediaAdacelBoostrix
- Other names
- diphtheria, tetanus, and acellular pertussis vaccineDTPa vaccine
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on diphtheria + tetanus + acellular pertussis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria + tetanus + acellular pertussis vaccine.